| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | YL54 | CTRPv2 | pan-cancer | AAC | 0.0061 | 0.9 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | -0.0052 | 0.9 |
| mRNA | NSC632839 | CTRPv2 | pan-cancer | AAC | -0.0052 | 0.9 |
| mRNA | Cisplatin | GDSC1000 | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | BRD-A02303741 | CTRPv2 | pan-cancer | AAC | -0.0058 | 0.9 |
| mRNA | BRD1812 | CTRPv2 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | GW843682X | GDSC1000 | pan-cancer | AAC | 0.0077 | 0.9 |
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | avrainvillamide | CTRPv2 | pan-cancer | AAC | 0.0058 | 0.9 |
| mRNA | BRD-K13185470 | CTRPv2 | pan-cancer | AAC | -0.0095 | 0.9 |